Damora Q2 net loss widens to $31.17 million

Reuters2026/08/10 20:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Damora posted a GAAP net loss of USD 31.17 million for the quarter ended June 30, 2026, widening from USD 3.44 million a year earlier.
Operating loss widened to USD 34.99 million from USD 3.42 million, as operating expenses climbed to USD 34.99 million.
RD expense rose to USD 25.54 million from USD 1.47 million, while GA costs increased to USD 9.45 million from USD 1.96 million.
Other income swung to USD 4.08 million from a loss of USD 12,000, driven by higher interest income following recent financings.
Damora said it recently initiated a Phase 1/1b trial of lead candidate DMR-001, targeting proof-of-concept readouts starting mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342307), on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Damora Q2 net loss widens to $31.17 million

You may also like

Crypto prices